CN111454207B - 用于治疗精神分裂症的缓释制剂中阿立哌唑衍生物的结晶方法 - Google Patents
用于治疗精神分裂症的缓释制剂中阿立哌唑衍生物的结晶方法 Download PDFInfo
- Publication number
- CN111454207B CN111454207B CN202010375290.3A CN202010375290A CN111454207B CN 111454207 B CN111454207 B CN 111454207B CN 202010375290 A CN202010375290 A CN 202010375290A CN 111454207 B CN111454207 B CN 111454207B
- Authority
- CN
- China
- Prior art keywords
- mixture
- temperature
- formula
- aripiprazole
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 153
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical class ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 title abstract description 39
- 238000002425 crystallisation Methods 0.000 title description 72
- 201000000980 schizophrenia Diseases 0.000 title description 8
- 238000009472 formulation Methods 0.000 title description 6
- 238000013268 sustained release Methods 0.000 title description 6
- 239000012730 sustained-release form Substances 0.000 title description 6
- 238000000034 method Methods 0.000 claims abstract description 144
- 239000002245 particle Substances 0.000 claims abstract description 132
- 150000001875 compounds Chemical class 0.000 claims abstract description 59
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 92
- 239000002904 solvent Substances 0.000 claims description 73
- 239000000243 solution Substances 0.000 claims description 66
- 238000001816 cooling Methods 0.000 claims description 56
- 238000000265 homogenisation Methods 0.000 claims description 51
- 229940079593 drug Drugs 0.000 claims description 47
- 239000003814 drug Substances 0.000 claims description 47
- 230000008569 process Effects 0.000 claims description 39
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 34
- 229940011051 isopropyl acetate Drugs 0.000 claims description 34
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 18
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 17
- 238000013019 agitation Methods 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 239000012453 solvate Substances 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 15
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 12
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 12
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims description 12
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims description 12
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 claims description 12
- BKIMMITUMNQMOS-UHFFFAOYSA-N nonane Chemical compound CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 claims description 12
- RSJKGSCJYJTIGS-UHFFFAOYSA-N undecane Chemical compound CCCCCCCCCCC RSJKGSCJYJTIGS-UHFFFAOYSA-N 0.000 claims description 12
- 239000003186 pharmaceutical solution Substances 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 9
- 238000010438 heat treatment Methods 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 claims description 7
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 claims description 7
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 claims description 7
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 6
- 229940043232 butyl acetate Drugs 0.000 claims description 6
- 229940093499 ethyl acetate Drugs 0.000 claims description 6
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims description 6
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 6
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 claims description 6
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 6
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 6
- 229940090181 propyl acetate Drugs 0.000 claims description 6
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 claims description 6
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 6
- 229960004372 aripiprazole Drugs 0.000 abstract description 54
- 239000013078 crystal Substances 0.000 abstract description 47
- 239000007924 injection Substances 0.000 abstract description 24
- 238000002347 injection Methods 0.000 abstract description 24
- 125000001931 aliphatic group Chemical group 0.000 abstract description 2
- DDINXHAORAAYAD-UHFFFAOYSA-N aripiprazole lauroxil Chemical compound C1=C2N(COC(=O)CCCCCCCCCCC)C(=O)CCC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC(Cl)=C1Cl DDINXHAORAAYAD-UHFFFAOYSA-N 0.000 description 89
- 229960003798 aripiprazole lauroxil Drugs 0.000 description 88
- 230000008025 crystallization Effects 0.000 description 69
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 63
- 238000001953 recrystallisation Methods 0.000 description 42
- 238000009826 distribution Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 238000012546 transfer Methods 0.000 description 14
- 238000013400 design of experiment Methods 0.000 description 13
- 238000010899 nucleation Methods 0.000 description 13
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 12
- 230000006911 nucleation Effects 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 229940035044 sorbitan monolaurate Drugs 0.000 description 9
- 238000004090 dissolution Methods 0.000 description 8
- 239000002244 precipitate Substances 0.000 description 8
- 239000008186 active pharmaceutical agent Substances 0.000 description 7
- -1 lauroyl aripiprazole Chemical compound 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- 238000013459 approach Methods 0.000 description 6
- 239000007972 injectable composition Substances 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- 238000010926 purge Methods 0.000 description 6
- 238000013461 design Methods 0.000 description 5
- 229940088679 drug related substance Drugs 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 238000007918 intramuscular administration Methods 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000002002 slurry Substances 0.000 description 5
- 229920001213 Polysorbate 20 Polymers 0.000 description 4
- 230000002301 combined effect Effects 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 238000013401 experimental design Methods 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000007927 intramuscular injection Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
- 229940068977 polysorbate 20 Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- STDYTJDGBXCCRG-UHFFFAOYSA-N Aripiprazole cavoxil Chemical compound C1=C2N(COC(=O)CCCCC)C(=O)CCC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC(Cl)=C1Cl STDYTJDGBXCCRG-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000013529 heat transfer fluid Substances 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 208000024714 major depressive disease Diseases 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000003134 recirculating effect Effects 0.000 description 3
- 230000002269 spontaneous effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000020925 Bipolar disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 229940005529 antipsychotics Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000004810 polytetrafluoroethylene Substances 0.000 description 2
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 2
- 238000010903 primary nucleation Methods 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000010900 secondary nucleation Methods 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- RDYWTOWUSVAZGN-UHFFFAOYSA-N 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-1-(hydroxymethyl)-3,4-dihydroquinolin-2-one Chemical compound C1=C2N(CO)C(=O)CCC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC(Cl)=C1Cl RDYWTOWUSVAZGN-UHFFFAOYSA-N 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100233916 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) KAR5 gene Proteins 0.000 description 1
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000028683 bipolar I disease Diseases 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011550 data transformation method Methods 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000011152 fibreglass Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 239000006191 orally-disintegrating tablet Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011112 process operation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000002400 serotonin 2A antagonist Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010375290.3A CN111454207B (zh) | 2014-08-25 | 2015-08-24 | 用于治疗精神分裂症的缓释制剂中阿立哌唑衍生物的结晶方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462041341P | 2014-08-25 | 2014-08-25 | |
| US62/041,341 | 2014-08-25 | ||
| PCT/US2015/046525 WO2016032950A1 (en) | 2014-08-25 | 2015-08-24 | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia |
| CN202010375290.3A CN111454207B (zh) | 2014-08-25 | 2015-08-24 | 用于治疗精神分裂症的缓释制剂中阿立哌唑衍生物的结晶方法 |
| CN201580057857.XA CN107106556B (zh) | 2014-08-25 | 2015-08-24 | 用于治疗精神分裂症的缓释制剂中阿立哌唑衍生物的结晶方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580057857.XA Division CN107106556B (zh) | 2014-08-25 | 2015-08-24 | 用于治疗精神分裂症的缓释制剂中阿立哌唑衍生物的结晶方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111454207A CN111454207A (zh) | 2020-07-28 |
| CN111454207B true CN111454207B (zh) | 2024-10-18 |
Family
ID=55347322
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580057857.XA Active CN107106556B (zh) | 2014-08-25 | 2015-08-24 | 用于治疗精神分裂症的缓释制剂中阿立哌唑衍生物的结晶方法 |
| CN202010375290.3A Active CN111454207B (zh) | 2014-08-25 | 2015-08-24 | 用于治疗精神分裂症的缓释制剂中阿立哌唑衍生物的结晶方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580057857.XA Active CN107106556B (zh) | 2014-08-25 | 2015-08-24 | 用于治疗精神分裂症的缓释制剂中阿立哌唑衍生物的结晶方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (5) | US10064859B2 (enExample) |
| EP (2) | EP3865476B1 (enExample) |
| JP (2) | JP6591546B2 (enExample) |
| CN (2) | CN107106556B (enExample) |
| AU (2) | AU2015306910B2 (enExample) |
| CA (1) | CA2959329C (enExample) |
| CY (1) | CY1124058T1 (enExample) |
| DK (1) | DK3185867T3 (enExample) |
| ES (2) | ES2994850T3 (enExample) |
| HR (1) | HRP20210551T1 (enExample) |
| HU (1) | HUE054641T2 (enExample) |
| IL (1) | IL250661B (enExample) |
| LT (1) | LT3185867T (enExample) |
| MA (2) | MA55917A (enExample) |
| PL (1) | PL3185867T3 (enExample) |
| PT (1) | PT3185867T (enExample) |
| RS (1) | RS61709B1 (enExample) |
| SI (1) | SI3185867T1 (enExample) |
| SM (1) | SMT202100212T1 (enExample) |
| WO (1) | WO2016032950A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2885196C (en) | 2012-09-19 | 2021-06-22 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
| US10016415B2 (en) | 2014-08-18 | 2018-07-10 | Alkermes Pharma Ireland Limited | Aripiprazole prodrug compositions |
| MA55917A (fr) * | 2014-08-25 | 2022-03-16 | Alkermes Pharma Ireland Ltd | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie |
| WO2016181406A1 (en) * | 2015-05-08 | 2016-11-17 | Davuluri Ramamohan Rao | Improved process for the preparation of aripiprazole with reduced particle size |
| WO2018104953A1 (en) * | 2016-12-07 | 2018-06-14 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 7-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]butoxy}-2oxo-3,4-dihydro-2h-quinolin-1-yl)methyl dodecanoate |
| JP7246364B2 (ja) | 2017-07-28 | 2023-03-27 | インテルキム、ソシエダッド アノニマ | アリピプラゾールラウロキシルの調製方法 |
| CN110218209B (zh) * | 2018-03-02 | 2022-09-30 | 上海现代药物制剂工程研究中心有限公司 | 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用 |
| US11273158B2 (en) | 2018-03-05 | 2022-03-15 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
| CN113105389B (zh) * | 2021-04-16 | 2022-04-08 | 江苏海洋大学 | 一种阿立哌唑药物共晶及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| CN103561746A (zh) * | 2011-03-18 | 2014-02-05 | 奥克梅斯制药爱尔兰有限公司 | 包含脱水山梨糖醇酯的药物组合物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR033485A1 (es) * | 2001-09-25 | 2003-12-26 | Otsuka Pharma Co Ltd | Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma |
| US20050032811A1 (en) | 2003-08-06 | 2005-02-10 | Josiah Brown | Methods for administering aripiprazole |
| AU2004285448C1 (en) * | 2003-10-23 | 2021-08-19 | Otsuka Pharmaceutical Co., Ltd. | Controlled release sterile injectable aripiprazole formulation and method |
| TWI371274B (en) * | 2003-10-23 | 2012-09-01 | Bristol Myers Squibb Co | Process for making sterile aripiprazole of desired mean particle size |
| SI2234617T2 (sl) | 2007-12-19 | 2025-05-30 | Janssen Pharmaceutica Nv | Režim odmerjanja v zvezi z dolgodelujočimi paliperidonijevimi estri za injiciranje |
| US20110003823A1 (en) | 2008-08-01 | 2011-01-06 | Alpha Synergy Development, Inc. | Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage |
| EP2445502B2 (en) * | 2009-06-25 | 2022-09-28 | Alkermes Pharma Ireland Limited | Heterocyclic compounds for the treatment of neurological and psychological disorders |
| WO2012077134A1 (en) * | 2010-12-07 | 2012-06-14 | Ind-Swift Laboratories Limted | Process for preparing aripiprazole polymorphs |
| CA2824045C (en) * | 2011-01-07 | 2019-04-09 | Neodyne Biosciences, Inc. | Wound or skin treatment devices and methods |
| US10004807B2 (en) * | 2012-03-19 | 2018-06-26 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
| CA2885196C (en) * | 2012-09-19 | 2021-06-22 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions having improved storage stability |
| MA55917A (fr) * | 2014-08-25 | 2022-03-16 | Alkermes Pharma Ireland Ltd | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie |
-
2015
- 2015-08-24 MA MA055917A patent/MA55917A/fr unknown
- 2015-08-24 CN CN201580057857.XA patent/CN107106556B/zh active Active
- 2015-08-24 EP EP21150116.8A patent/EP3865476B1/en active Active
- 2015-08-24 SM SM20210212T patent/SMT202100212T1/it unknown
- 2015-08-24 DK DK15836431.5T patent/DK3185867T3/da active
- 2015-08-24 LT LTEP15836431.5T patent/LT3185867T/lt unknown
- 2015-08-24 CN CN202010375290.3A patent/CN111454207B/zh active Active
- 2015-08-24 WO PCT/US2015/046525 patent/WO2016032950A1/en not_active Ceased
- 2015-08-24 MA MA40480A patent/MA40480B1/fr unknown
- 2015-08-24 CA CA2959329A patent/CA2959329C/en active Active
- 2015-08-24 AU AU2015306910A patent/AU2015306910B2/en active Active
- 2015-08-24 HU HUE15836431A patent/HUE054641T2/hu unknown
- 2015-08-24 PT PT158364315T patent/PT3185867T/pt unknown
- 2015-08-24 US US14/833,638 patent/US10064859B2/en active Active
- 2015-08-24 HR HRP20210551TT patent/HRP20210551T1/hr unknown
- 2015-08-24 EP EP15836431.5A patent/EP3185867B1/en active Active
- 2015-08-24 ES ES21150116T patent/ES2994850T3/es active Active
- 2015-08-24 JP JP2017530956A patent/JP6591546B2/ja active Active
- 2015-08-24 RS RS20210433A patent/RS61709B1/sr unknown
- 2015-08-24 ES ES15836431T patent/ES2862098T3/es active Active
- 2015-08-24 SI SI201531576T patent/SI3185867T1/sl unknown
- 2015-08-24 PL PL15836431T patent/PL3185867T3/pl unknown
-
2017
- 2017-02-19 IL IL250661A patent/IL250661B/en active IP Right Grant
-
2018
- 2018-07-24 US US16/043,721 patent/US10478434B2/en active Active
-
2019
- 2019-09-18 JP JP2019169473A patent/JP2019210296A/ja active Pending
- 2019-10-08 US US16/595,608 patent/US10973816B2/en active Active
-
2020
- 2020-11-04 AU AU2020264303A patent/AU2020264303B2/en active Active
-
2021
- 2021-03-24 US US17/211,352 patent/US11883394B2/en active Active
- 2021-04-13 CY CY20211100318T patent/CY1124058T1/el unknown
-
2023
- 2023-12-18 US US18/543,767 patent/US20240245676A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
| CN103561746A (zh) * | 2011-03-18 | 2014-02-05 | 奥克梅斯制药爱尔兰有限公司 | 包含脱水山梨糖醇酯的药物组合物 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111454207B (zh) | 用于治疗精神分裂症的缓释制剂中阿立哌唑衍生物的结晶方法 | |
| JP4376518B2 (ja) | サブミクロン粒子の懸濁物を調製する方法 | |
| CN103561746A (zh) | 包含脱水山梨糖醇酯的药物组合物 | |
| JP2020513023A (ja) | ルマテペロンｐ−トシラートの非晶質形態および固体分散体 | |
| CN1761454A (zh) | 小颗粒的制备方法 | |
| CN1870987A (zh) | 制备紫杉醇亚微米颗粒的方法 | |
| PT107433A (pt) | Processo de redução e controlo do tamanho de partícula | |
| Kawakami et al. | Phase separation of supersaturated solution created from amorphous solid dispersions: Relevance to oral absorption | |
| TW202104225A (zh) | 原肌球蛋白相關激酶（ｔｒｋ）抑制劑之醫藥調配物 | |
| CN101163704A (zh) | 大粒径他达那非及其制备方法 | |
| JP2008520751A (ja) | 大粒子サイズを有するタダラフィル及びそれを調製する方法 | |
| HK40057525B (en) | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia | |
| HK40057525A (en) | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia | |
| NZ729479B2 (en) | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia | |
| HK1246636A1 (en) | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia | |
| HK1246636B (en) | Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia | |
| JP2012214525A (ja) | ポリ乳酸微粒子含有凍結乾燥組成物の製造方法 | |
| JP2005536525A (ja) | 制御された沈澱（再結晶化）法を用いて、製造された結晶質薬物粒子 | |
| WO2015147665A1 (en) | Process for manufacturing brinzolamide ophthalmic suspension and eye drops formulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |